Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Immunity|June 20, 2006
Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytesKnut Schäkel, Matthias von Kietzell, Anja Hänsel, et al.Archives of Dermatology|November 23, 2006
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigusStefan Beissert, Thomas Werfel, Uta Frieling, et al.Arthritis Research & Therapy|March 6, 2009
High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacyNicolas Hunzelmann, Pia Moinzadeh, Ekkehard Genth, et al.Archives of Dermatology|December 19, 2007
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoidStefan Beissert, Thomas Werfel, Uta Frieling, et al.Archives of Dermatology|June 20, 2002
Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old ageBerthold Rzany, Karin Partscht, Martin Jung, et al.The Journal of Allergy and Clinical Immunology|June 4, 2011
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseMarcus Maurer, Sabine Altrichter, Thomas Bieber, et al.Arthritis Research & Therapy|October 25, 2011
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical featuresRudolf Mierau, Pia Moinzadeh, Gabriela Riemekasten, et al.Journal of the American Academy of Dermatology|November 8, 2011
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of expertsDedee F Murrell, Benjamin S Daniel, Pascal Joly, et al.Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.Pageof 5